Your browser doesn't support javascript.
loading
Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol.
Takagi, Masatoshi; Ogawa, Chitose; Aoki-Nogami, Yuki; Iehara, Tomoko; Ishibashi, Eri; Imai, Minoru; Kihara, Tetsuro; Nobori, Kiyoshi; Hasebe, Kazuhisa; Mizutani, Shuki; Kimura, Toshimi; Nagata, Masashi; Yasuhara, Masato; Yoshimura, Kenichi; Yorozu, Pariko; Hosoi, Hajime; Koike, Ryuji.
Afiliación
  • Takagi M; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bunkyo-ku, Tokyo, 113-8519, Japan. m.takagi.ped@tmd.ac.jp.
  • Ogawa C; Department of Pediatric Oncology, National Cancer Center, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
  • Aoki-Nogami Y; Department of Pediatric Oncology, National Cancer Center, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.
  • Iehara T; Department of Pediatrics, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
  • Ishibashi E; University Research Administration Division, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Imai M; University Research Administration Division, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Kihara T; University Research Administration Division, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Nobori K; Medical Innovation Promotion Center, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Hasebe K; University Research Administration Division, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Mizutani S; University Research Administration Division, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Kimura T; Department of Pharmacodynamics, Tokyo Women's Medical University, Kawada-cho 8-1, Shinjuku-ku, Tokyo, 162-8666, Japan.
  • Nagata M; Department of Pharmacodynamics, Tokyo Medical and Dental University, Tokyo, Japan.
  • Yasuhara M; Department of Pharmacodynamics, Tokyo Medical and Dental University, Tokyo, Japan.
  • Yoshimura K; Innovative Clinical Research Center, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa, 920-8641, Japan.
  • Yorozu P; Medical Innovation Promotion Center, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Hosoi H; Department of Pediatrics, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
  • Koike R; Medical Innovation Promotion Center, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
BMC Pediatr ; 19(1): 31, 2019 01 26.
Article en En | MEDLINE | ID: mdl-30684955
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Proyectos de Investigación / Ensayos Clínicos Fase I como Asunto / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Child / Child, preschool / Humans Idioma: En Revista: BMC Pediatr Asunto de la revista: PEDIATRIA Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ftalazinas / Piperazinas / Proyectos de Investigación / Ensayos Clínicos Fase I como Asunto / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Child / Child, preschool / Humans Idioma: En Revista: BMC Pediatr Asunto de la revista: PEDIATRIA Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido